Thrivent Financial for Lutherans Has $670,000 Stock Position in LivaNova PLC (NASDAQ:LIVN)

Thrivent Financial for Lutherans lowered its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 57.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 12,757 shares of the company's stock after selling 17,146 shares during the quarter. Thrivent Financial for Lutherans' holdings in LivaNova were worth $670,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Fifth Third Bancorp lifted its stake in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company's stock worth $37,000 after purchasing an additional 332 shares in the last quarter. Hexagon Capital Partners LLC increased its position in LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock valued at $37,000 after buying an additional 370 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in LivaNova during the 2nd quarter valued at about $88,000. Central Pacific Bank Trust Division acquired a new stake in LivaNova during the 3rd quarter valued at approximately $178,000. Finally, TradeLink Capital LLC purchased a new stake in LivaNova in the second quarter valued at $208,000. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on LIVN. Mizuho reduced their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, October 31st. Robert W. Baird increased their price objective on LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. The Goldman Sachs Group initiated coverage on LivaNova in a research note on Friday, October 4th. They set a "buy" rating and a $65.00 price target on the stock. Needham & Company LLC restated a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. Finally, StockNews.com cut LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Saturday, November 16th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $69.17.

LivaNova Trading Down 1.3 %

Shares of LIVN traded down $0.69 during midday trading on Thursday, hitting $50.50. The stock had a trading volume of 494,912 shares, compared to its average volume of 608,236. The business has a 50-day simple moving average of $52.28 and a two-hundred day simple moving average of $51.95. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a fifty-two week low of $43.15 and a fifty-two week high of $64.47. The firm has a market cap of $2.74 billion, a P/E ratio of 121.88 and a beta of 0.98.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.